Editor’s Note
**Editor’s Note:** JDBIO Co., Ltd. takes center stage as the main sponsor of AMWC KOREA 2026, showcasing its core medical aesthetic portfolio to a global audience of professionals and buyers.
Global medical aesthetic company JDBIO Co., Ltd. (CEO Kim Jin-dong) announced its participation as the main sponsor at the ‘AMWC KOREA 2026’ beauty and anti-aging academic conference.
As the main sponsor, JDBIO unveiled its core medical aesthetic portfolio. During the event, the company conducted product introductions and business meetings, drawing high interest from domestic and international medical professionals, global buyers, and distribution partners. This provided a meaningful platform to showcase JDBIO’s unique technological capabilities and market competitiveness.
At the exhibition, JDBIO presented its botulinum toxin products OneTox and Red Tox, based on high-purity refining technology, as well as hyaluronic acid fillers RICHESSE™ Red Volume No.7 and No.9, featuring HLD patented technology, and body fillers DEMEI™ Body 60 and Body 100. Each product represents a core lineup developed from JDBIO’s accumulated biotechnology and quality management capabilities.
On the second day of the conference, during JDBIO’s invited luncheon session, CEO Kim Jin-dong delivered a presentation on ‘The Future of Medical Aesthetics and Innovation in Biotechnology,’ sharing the company’s market direction and next-generation growth vision. Following this, aesthetic medical professionals introduced next-generation skin booster technology utilizing the new substance CHP, presenting clinical data and application cases under the theme ‘Overcoming the Limitations of Existing Skin Boosters through Beyond Hydration CHP.’
Additionally, JDBIO’s subsidiary JD Skin Lab unveiled the P.E.C 360 Revine line from its premium skincare brand DR. RICHESSE. This line is characterized by a proprietary formulation technology based on PDRN, Exosome, and Collagen.
